[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit ::
:: Volume 5 - The Spring Supplement of Shefaye Khatam 2 - ::
Shefaye Khatam 2017, 5 - The Spring Supplement of Shefaye Khatam 2 -: 112-112 Back to browse issues page
P 81: Omega-3 Fatty Acid and Oxylipins in Management of Alzheimer Disease
Kimia Tarrah *
Student of Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , k.tarrah@yahoo.com
Abstract:   (248 Views)

Neurodegenerative disease are characterized by the progressive loss of neurons from specific origins of the CNS .Alzheimer disease (AD) is a neurodegenerative disorder which affect brain regains that control memory and ability to learn. It is estimated that 27 million people are affected word wide and this number is expected to triple by 2050 due to increase of the population life expectancy. AD is becoming one of the most prevalent neurodegenerative conditions worldwide. Although the disease progression is becoming better understood, current medical interventions can only ameliorate some of the symptoms but cannot slow disease progression. Neuroinflammation, a specialized immune response that takes place in the central nervous system, has been linked to neurodegenerative diseases, and specially, it has been considered as a hallmark of Alzheimer disease. It plays an important role in the advancement of this disorder. Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) are involved in both the reduction in and resolution of inflammation. These effects may be mediated by the anti-inflammatory and proresolving effects of bioactive lipid mediators (oxylipins) derived from n–3 PUFAs [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] in fish oil. Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids, (DHA) and (EPA), may have effects in psychiatric and behavioral symptoms in AD. Several studies indicate that Both DHA and EPA can reduce neuroinflammation and cognitive decline, but EPA positively influences mood disorders, whereas DHA maintains normal brain structure. The unique anti-inflammatory and pro-resolving properties of oxylipins from individual n–3 PUFAs will enable the discovery of novel disease-management strategies in AD.

Keywords: Omega-3 fatty acid, Oxylipins, Alzheimer disease
Full-Text [PDF 229 kb]   (151 Downloads)    
Type of Study: Review --- Open Access, CC-BY-NC | Subject: Basic research in Neuroscience



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tarrah K. P 81: Omega-3 Fatty Acid and Oxylipins in Management of Alzheimer Disease. Shefaye Khatam. 2017; 5 (S2) :112-112
URL: http://shefayekhatam.ir/article-1-1267-en.html
Volume 5 - The Spring Supplement of Shefaye Khatam 2 - Back to browse issues page
مجله علوم اعصاب شفای خاتم The Neuroscience Journal of Shefaye Khatam
Persian site map - English site map - Created in 0.049 seconds with 787 queries by yektaweb 3506